Skip to main content
Lookout logo

Lookout

Security and trust center evidence

lookout.comSecurityLast verified 17 Sep 2026

Summary

Lookout has 3 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is FedRAMP: FedRAMP Authorized. This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.

Reviewer brief

As of 17 Sep 2026, Lookout is listed in the FedRAMP registry as FedRAMP Authorized, with the authorization originally issued on 29 Apr 2020 and audited by Schellman Compliance, LLC. As of 17 Sep 2026, Lookout is listed in the CSA STAR registry at Level 1 (self-assessment/CAIQ), with the entry issued 11 Mar 2021. As of 17 Sep 2026, Lookout is listed in the EU-US Data Privacy Framework registry as Active, covering SW-US, EU-US, and UK Extension Certifications, originally issued 4 Oct 2016 and set to expire 22 Jul 2027. As of 17 Sep 2026, no public evidence found for SOC 2 or HIPAA for Lookout. As of 17 Sep 2026, no subprocessors were listed in the evidence provided for Lookout.

  • FedRAMP: listed in FedRAMP registry as FedRAMP Authorized (issued 29 Apr 2020; audited by Schellman Compliance, LLC) — as of 17 Sep 2026.
  • CSA STAR: listed in CSA STAR registry at Level 1 self-assessment (CAIQ), issued 11 Mar 2021 — as of 17 Sep 2026.
  • EU-US Data Privacy Framework: listed in DPF registry as Active (SW-US, EU-US, UK Extension), issued 4 Oct 2016, expires 22 Jul 2027 — as of 17 Sep 2026.

Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.

Among security vendors

3verified rows

Category median 1, across 174 indexed security vendors. Lookout has more verified rows than 100 percent of them.

cloud securityendpoint protectionmobile securitythreat detection

Compliance grid

Subprocessors

No subprocessor list captured yet.

Similar vendors with evidence

Related by product tags and the Security category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.